Copenhagen biotech startup Traitomic, spun out of Carlsberg, has raised €20 million in a Series A round led by Sofinnova Partners, with participation from EIFO, The Footprint Firm, PSV Hafnium, Nordic Foodtech VC, and SVG Ventures. It is the company’s first external investment since the spinout, in which Carlsberg cut its stake to between 33 and 50 percent.

The journey started inside the Carlsberg Research Laboratory, where researchers developed FIND-IT, a screening platform originally built to improve barley for brewing. The technology, described by Carlsberg scientists in Science Advances in 2022 using a library of 500,000 barley plants, screens conventionally bred populations for specific genetic changes, finding useful naturally occurring variants in plants and microbes without directly editing any genes. In effect, it promises gene-editing outcomes without gene editing, avoiding the regulatory and market hurdles that still surround genetically modified and gene-edited products in much of the world.

When Carlsberg gave a small team the licence to commercialise the technology, it came with one stipulation: stay away from brewing. Carlsberg retains ownership of FIND-IT’s IP and the brewing rights, while Traitomic holds an exclusive licence for everything else.

From Subsidiary to Independent Growth Business

Since then, the Copenhagen-based company, led by CEO and co-founder Gustav Hambraeus and now 30 people strong, has built what it calls the world’s largest commercial trait portfolio. It has delivered 116 traits to 47 customers across 32 organisms, from crop improvement to industrial enzymes, and has around 100 more traits in pre-commercial assessment with clients.

“We are already seeing demand from some of the world’s largest companies. It is that combination of strong technology, real industrial interest, and global potential that we are investing in,”

said Sara Sande, Managing Director and Partner in Direct Thematic Venture at EIFO.

With the new capital, Traitomic is moving from Carlsberg subsidiary to independent growth business.

“It’s like a little bit of a teenager. Now we need to move out,”

said Gustav Hambraeus.

The plan is to expand into the US and Australia, with an Australian branch focused on plant trait development, and to broaden the offering from trait discovery to end-to-end development inside customers’ own crops and strains.

The company is also betting that its non-GE approach remains attractive even as regulation loosens: new EU rules passed in June 2026 will ease the regulation of some gene-edited plants from July 2028, potentially eroding the advantage Traitomic holds over gene-editing rivals such as Tropic and Rainbow Crops. For plant breeders, food manufacturers, and retailers who want improved crop genetics without the commercial uncertainty of gene-edited products, Traitomic’s pitch is that nature already holds the variants, you just have to find them.